Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402180 | 0.87 | BTK (0.55) | BTK | |
| SCHEMBL13860120 | 0.83 | BTK (0.48) | BTK | |
| SCHEMBL6116153 | 0.79 | BTK (0.74) | BTK | |
| SCHEMBL8402192 | 0.77 | BTK (0.56) | BTK | |
| SCHEMBL13860029 | 0.76 | BTK (0.53) | BTK | |
| SCHEMBL13860028 | 0.76 | BTK (0.53) | BTK | |
| SCHEMBL6115828 | 0.75 | BTK (0.76) | BTK | |
| SCHEMBL8402104 | 0.73 | BTK (0.58) | BTK | |
| SCHEMBL8402083 | 0.73 | BTK (0.58) | BTK | |
| SCHEMBL14810861 | 0.72 | TOP2A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | Principia Biophama Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | Principia Biophama Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | Principia Biophama Inc. (US) | 2014-04-17 | — | — | US | disclosed |
| WO-2012158810-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012158810-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107151-A1 | TYROSINE KINASE INHIBITORS | BMX, BLK, ITK | BTK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.